Today's Updates

TRPA1 Antagonist Shows Delayed but Meaningful Effect on IPF Cough Marlies Wijsenbeen, MD, PhD
Published Date: 20 Oct 2026

Marlies Wijsenbeek, MD, PhD, of Erasmus MC discusses BI 1839100, a TRPA1 antagonist, which missed its week-4 endpoint in a phase 2/2b trial.

Read More
Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD Chelsie Derman
Published Date: 20 Oct 2026

In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL.

Read More
ASPEN: Sputum Color Associated With Bronchiectasis Disease Activity Victoria Johnson
Published Date: 20 Oct 2026

A post hoc analysis linked more purulent patient-reported sputum to higher neutrophil elastase activity and greater bronchiectasis disease activity.

Read More
Sphingolipid Profiles May Distinguish IPF from Fibrotic HP
Published Date: 20 Oct 2026

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

Read More
CHEST 2026: Day 1 Recap — 5 Headlines to Know
Published Date: 20 Oct 2026

CHEST 2026: Day 1 Recap — 5 Headlines to Know

Read More
PAH Combination Therapy and Escalation: Clinical Forum Perspectives
Published Date: 20 Oct 2026

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

Read More
APP Experts Discuss Earlier Biologic Use in Asthma and COPD
Published Date: 20 Oct 2026

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

Read More
NeurologyLive® Friday 5 — October 16, 2026 Isabella Ciccone, MPH
Published Date: 20 Oct 2026

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.

Read More
RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial Louie Pasculli
Published Date: 20 Oct 2026

Pivotal AFFINITY DUCHENNE results showed microdystrophin expression above the prespecified threshold in 93% of evaluable participants, with preliminary functional findings favoring treatment over external controls.

Read More
Nipocalimab in Myasthenia Gravis: Real-World Use, Long-Term Safety, and the Road Ahead Marco Meglio, Leonard Dragone, MD, PhD
Published Date: 20 Oct 2026

Leonard Dragone, MD, PhD, Disease Area Leader at Johnson & Johnson, discusses how nipocalimab is being incorporated into generalized MG care, what long-term data show, and where J&J sees the therapy’s role evolving.

Read More
Oral Icotrokinra Sustains UC Response Through 76 Weeks in ANTHEM-UC LTE Maria Abreu, MD
Published Date: 20 Oct 2026

Maria Abreu, MD, discusses 76-week ANTHEM-UC extension data showing once-daily oral icotrokinra maintained efficacy with no new safety signals in UC.

Read More
Subcutaneous Infliximab Outperforms IV in Ileal Crohn’s Disease Analysis
Published Date: 20 Oct 2026

Subcutaneous Infliximab Outperforms IV in Ileal Crohn’s Disease Analysis

Read More
VERDICT Links Vedolizumab Disease Clearance to Fewer UC Complications
Published Date: 20 Oct 2026

VERDICT Links Vedolizumab Disease Clearance to Fewer UC Complications

Read More
Q&A: Nemolizumab Sustains Itch, Skin Gains in Early Responders at 3 Years
Published Date: 20 Oct 2026

Q&A: Nemolizumab Sustains Itch, Skin Gains in Early Responders at 3 Years

Read More
Bitopertin Meets All Endpoints in Phase 3 APOLLO Trial for EPP
Published Date: 20 Oct 2026

Bitopertin Meets All Endpoints in Phase 3 APOLLO Trial for EPP

Read More

Latest News

Verekitug's Quarterly Dosing Cuts Asthma Burden, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler discusses why less frequent dosing matters to patients with severe asthma, plus VALIANT's safety profile and what's next for the field.

Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations

Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

Biologic Access in Asthma and COPD: Clinical Forum Perspectives

Biologic Access in Asthma and COPD: Clinical Forum Perspectives

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Clinical Forum Weighs in: Biologic Selection in Asthma and COPD

Clinical Forum Weighs in: Biologic Selection in Asthma and COPD

Clinical Forum Insights: When to Escalate to Biologics in Asthma and COPD?

Clinical Forum Insights: When to Escalate to Biologics in Asthma and COPD?

CHEST 2026 Preview: Late-Breakers to Watch Out For

CHEST 2026 Preview: Late-Breakers to Watch Out For

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Residual Asthma Exacerbations on Biologics Vary by Mechanism

Residual Asthma Exacerbations on Biologics Vary by Mechanism

Dupilumab's IL-4/IL-13 Blockade Drives Efficacy Edge in EVEREST Guy Brusselle, MD, PhD

Guy Brusselle, MD, PhD, explains why broader cytokine blockade with dupilumab outpaced omalizumab, and why nonremitters in EVEREST still improved.

Verekitug Reduces Asthma Exacerbations Up to 87%, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Phase 2 VALIANT data show the anti-TSLP receptor antibody sharply reduced exacerbations in patients with high eosinophil counts.

8 Pulmonology Headlines You Missed in Q3 2026

8 Pulmonology Headlines You Missed in Q3 2026

8 Pulmonology Headlines You Missed in September 2026

8 Pulmonology Headlines You Missed in September 2026

Dupilumab Outperforms Omalizumab for Asthma Remission in Phase 4 EVEREST Guy Brusselle, MD, PhD

Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

What 2 Seasons of Arexvy Data Reveal About RSV-Related Risk Reduction Ann Falsey, MD

Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

Latest News

Verekitug's Quarterly Dosing Cuts Asthma Burden, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler discusses why less frequent dosing matters to patients with severe asthma, plus VALIANT's safety profile and what's next for the field.

Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations

Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

Biologic Access in Asthma and COPD: Clinical Forum Perspectives

Biologic Access in Asthma and COPD: Clinical Forum Perspectives

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Clinical Forum Weighs in: Biologic Selection in Asthma and COPD

Clinical Forum Weighs in: Biologic Selection in Asthma and COPD

Clinical Forum Insights: When to Escalate to Biologics in Asthma and COPD?

Clinical Forum Insights: When to Escalate to Biologics in Asthma and COPD?

CHEST 2026 Preview: Late-Breakers to Watch Out For

CHEST 2026 Preview: Late-Breakers to Watch Out For

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Residual Asthma Exacerbations on Biologics Vary by Mechanism

Residual Asthma Exacerbations on Biologics Vary by Mechanism

Dupilumab's IL-4/IL-13 Blockade Drives Efficacy Edge in EVEREST Guy Brusselle, MD, PhD

Guy Brusselle, MD, PhD, explains why broader cytokine blockade with dupilumab outpaced omalizumab, and why nonremitters in EVEREST still improved.

Verekitug Reduces Asthma Exacerbations Up to 87%, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Phase 2 VALIANT data show the anti-TSLP receptor antibody sharply reduced exacerbations in patients with high eosinophil counts.

8 Pulmonology Headlines You Missed in Q3 2026

8 Pulmonology Headlines You Missed in Q3 2026

8 Pulmonology Headlines You Missed in September 2026

8 Pulmonology Headlines You Missed in September 2026

Dupilumab Outperforms Omalizumab for Asthma Remission in Phase 4 EVEREST Guy Brusselle, MD, PhD

Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

What 2 Seasons of Arexvy Data Reveal About RSV-Related Risk Reduction Ann Falsey, MD

Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

News All Time

Insurance Formularies Holding Up Lower-Emission Asthma, COPD Inhalers

— Options that reduce greenhouse gases face lower rates of coverage and more administrative hurdles

Pulmonary NPs Debate Biologic Escalation in Asthma, COPD Care Victoria Johnson

Nurse practitioners discuss escalating biologic therapy for asthma and COPD, mucus plugging data, and access barriers.

7 Pulmonology Headlines You Missed in August 2026 Victoria Johnson

August 2026 pulmonology highlights include deupirfenidone's positive phase 2b ELEVATE-IPF results, FDA Fast Track for LTI-03, and more.

Lung Cancer Diagnosis Linked to Lung Microplastic Presence, Quantity Victoria Johnson

Paired airway and tissue sampling from 100 patients found greater microplastic burden in those with lung cancer.

Why Doctors Need to Complete the COPD or Asthma Workup to Rule Out Alpha-1 Kyle Hogarth, MD

Kyle Hogarth, MD, urges physicians to complete Alpha-1 testing during every COPD or asthma workup, warning that skipped tests delay diagnosis.

Childhood Pollution Exposure May Trigger COPD Polygenic Risk Victoria Johnson

A COPD genetic risk score was linked to reduced lung function growth from birth to age 6, but only in children with high air pollution exposure.

GRI-0621 Improves FVC, Reduces Fibrotic Biomarkers in IPF Victoria Johnson

The oral RARβ/γ agonist improved FVC and reduced fibrotic biomarkers over 12 weeks in a phase 2a trial presented at the ERS Congress 2026.

Ralinepag Improves Clinical Outcomes in Contemporary PAH Population Victoria Johnson

ADVANCE Outcomes at ERS 2026 demonstrated improved odds of improvement and reduced odds of worsening.

Q&A: PERFORM Data Support Triple Therapy in Milder Uncontrolled Asthma John Oppenheimer, MD

At ERS 2026, John Oppenheimer, MD, discusses how PERFORM supports earlier escalation in patients with uncontrolled, infrequently exacerbating asthma.

Zumilokibart Rapidly Suppresses FeNO in Phase 1b Asthma Data: Mario Castro, MD Mario Castro, MD, MPH

Castro, of University of Kansas discusses interim phase 1b data showing rapid, durable suppression in patients with mild to moderate asthma.

Dupilumab Scores on Win-Ratio Analysis in Pediatric Asthma: Sharon Dell, MD Sharon Dell, MD

Dell discusses an analysis of VOYAGE showing dupilumab more than doubled the odds of favorable asthma outcomes in children, regardless of baseline ICS dose.

PDGF Pathway in PAH: Setbacks and Promise, With Olivier Sitbon, MD, PhD Olivier Sitbon, MD, PhD

Olivier Sitbon, MD, PhD, reviews PDGF-targeted therapy in PAH, from imatinib's IMPRES trial to new prodrug and antibody approaches.

BEAM-302 Base Editing Sustains Protective AAT, With John Hurst, MBBS, PhD John Hurst, MBBS, PhD

Hurst discusses data showing durably raised protective AAT levels in patients with alpha-1 antitrypsin deficiency.

Semaglutide Cuts Asthma Attacks by up to 40% in Real-World Study Victoria Johnson

Semaglutide was linked to fewer asthma attacks and COPD flare-ups than sulfonylureas, with no effect seen for other GLP-1 therapies.

Tozorakimab Cuts COPD Exacerbations Across Eosinophil Levels: Frank Sciurba, MD Frank C. Sciurba, MD

Sciurba, of University of Pittsburgh, discusses full phase 3 OBERON and TITANIA results, including stronger responses in current smokers.

STAT6 Degraders: Accessible Biologic-Like Asthma Care? With Njira Lugogo, MD Njira Lugogo, MD

Lugogo, ofUniversity of Michigan, discusses how oral STAT6 degraders like KT-621 could expand biologic-like asthma treatment beyond highest severity.

Recommended News For You

Gotistobart Response Rate Bests Chemo in Pretreated NSCLC

More cancer cases in areas where incarceration rates are high: Study

Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.

FDA Approves Next-Gen Agent for Mantle Cell Lymphoma

Triplet Therapy Improves Posttransplant Outcomes in Myeloma

Obesity-associated cancers may be on the rise in Puerto Rico

Living in a more pedestrian-friendly area may reduce the risk of cancer and obesity-related diseases.

Recommended Articles For You

AI in Genomics: Decoding the Human Genome for Cancer Treatment 

Programmable Cell Therapies for Selective Removal of Dysfunctional Hematopoietic Cell Populations 

Amivantamab Plus Chemotherapy Outperforms Standard Care in Post-Osimertinib NSCLC 

Unlocking the Mysteries of Rhabdomyoma: A New Hope for Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap

2.

Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal

3.

Laryngeal Transplant Helped a Cancer Patient Speak Again in Pioneering Study

4.

The amount of liver tissue removed during gallbladder surgery has no discernible impact on overall survival.

5.

Long-Acting Interferon Therapy Approved for ET

1.

Molecular Network Mapping in Hematologic Disease

2.

Metabolic Reprogramming of the Tumor Microenvironment: Mechanisms, Clinical Relevance, and Emerging Therapeutic Strategies

3.

Hematopoietic Stem Cell Clonal Dynamics Across the Lifespan

4.

Connected Hematology Laboratory Networks for Automated Cross-Institution Data Exchange

5.

Digital Oncology Ecosystems Integrating Longitudinal Patient Trajectories: Transforming Cancer Care through Data-Driven Innovation

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

2.

Common side effects of cancer treatment and how they are managed

3.

Clinical Excellence in Hematology

4.

Best Practices in Hematology

5.

Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot